Recursion Pharmaceuticals, Inc. (RXRX) — Stock Score Summary

Recursion Pharmaceuticals, Inc. (RXRX) has a MoatMap StockRank of 7/100 based on Quality (28/100), Value (38/100), and Momentum (21/100) factor scores. The current signal is STRONG SELL. Recursion Pharmaceuticals is a highly speculative, cash-burning biotech platform that lacks the proven pricing power and high ROIC required by our quality compounder lens.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company pioneering an industrial-scale drug discovery platform that combines artificial intelligence, automation, and experimental biology to identify and advance novel therapeutic candidates. The company's 'Recursion Operating System' leverages machine learning to rapidly uncover potential treatments for a wide range of diseases, aiming to accelerate the drug discovery process. This unique, tech-driven approach to drug development provides a significant competitive moat, positioning it as an innovator in biotech.

Key Financial Metrics

Price$3.22
Market Cap$1.8B
P/E (Forward)-4.32
Price/Book1.97
Return on Equity-57.2%
Return on Invested Capital-48.5%
Debt/Equity7.06
Gross Margin0.0%
Operating Margin-1985.6%
Revenue Growth-56.1%
Free Cash Flow$-178M

Recursion Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Recursion Pharmaceuticals, Inc.’s (RXRX) StockRank?
MoatMap’s StockRank for Recursion Pharmaceuticals, Inc. (RXRX) is 7/100, with a Strong Sell signal. It is a composite of Quality (28), Value (38), and Momentum (21) factor ranks across MoatMap’s 19,000+ stock universe.
Does Recursion Pharmaceuticals, Inc. have an economic moat?
Recursion Pharmaceuticals, Inc. (RXRX) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Recursion Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Recursion Pharmaceuticals, Inc. (RXRX) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Recursion Pharmaceuticals, Inc. in?
Recursion Pharmaceuticals, Inc. (RXRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksRXRX deep dive reportAI ChampionsHow we score stocksSense-check another stock